To further evaluate the role of SGLT-2 Inhibitors on albuminuria, Ao-PWV and other markers of arterial aging, we performed a pre-specified secondary analysis of people with type 2 diabetes (T2DM) with preserved renal function and residual microalbuminuria despite maximum tolerated RAS inhibition who participated in a 24-week randomized controlled trial comparing Dapagliflozin and Ramipril (D+R) vs. Ramipril (R) only. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.